Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept Regimens in Nail and Plaque Psoriasis
NCT00581100Phase 4Completed
- Sponsor
- Pfizer
- Start
- Sep 2007
- Primary completion
- Aug 2009
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 4, randomised, open-label trial of etanercept in nail psoriasis and plaque psoriasis (2 arms), sponsored by Pfizer. Primary endpoint: Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score for Target Fingernail at 24 weeks. Started Sep 2007; status: completed.
02
Drugs
etanercept
03
Conditions
nail psoriasisplaque psoriasis
Beyond the preview
Go deeper on NCT00581100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00581100.